New Drugs and Clinical Trials · us
Psilocybin Therapy COMP360 Completes U.S. New Drug Application Submission, Awaiting FDA Review for Treatment-Resistant Depression
Two Phase 3 trials and one Phase 2 study have brought COMP360 to the regulatory review stage. Symptom improvements in some patients lasted up to six months, but efficacy, safety, and conditions for clinical use remain subject to regulatory assessment.
For patients who still respond poorly to antidepressants given at adequate doses and for adequate durations, the next treatment option often involves a long wait. Compass Pathways announced on November 9 that it had completed its New Drug Application submission to the U.S. Food and Drug Administration (FDA) for its psilocybin formulation COMP360, seeking approval for treatment-resistant depression. This development brings the therapy into the regulatory review stage, but it has not yet been approved.
COMP360 is an investigational drug made with synthetic psilocybin. Treatment-resistant depression generally refers to a condition in which patients have not experienced sufficient improvement after receiving at least two antidepressants at adequate doses and for adequate durations. According to Tablets & Capsules, COMP360 is administered as an oral capsule and must be used in a supervised clinical setting. If approved, delivering the treatment would therefore also involve arranging clinical facilities and care staff.
The core evidence for the application comes from two Phase 3 trials, COMP005 and COMP006, and one Phase 2b study. The company’s announcement stated that the three studies enrolled more than 1,000 patients in total and that each met its primary endpoint. This patient count covers all three studies and does not come entirely from the Phase 3 trials.
How long the effects last is a key question for this type of treatment. Psychiatric Times reported that in the COMP006 group receiving two 25-milligram doses of COMP360, 39% of participants had a reduction of at least 25% from baseline in their Montgomery–Åsberg Depression Rating Scale (MADRS) scores at week 6 and maintained that improvement through week 26. This offers an indication that some patients may experience sustained benefit, but it does not mean that 39% of patients achieved symptom remission or recovery.
This percentage alone also cannot establish the therapy’s overall benefit. Assessment must also consider differences from the control group, adverse events, and subsequent treatment needs; the submission announcement did not present these data in full. Thus, whether a study met its primary endpoint and which patients the treatment is suitable for, and whether its benefits outweigh its risks, remain questions at different levels. The latter questions will be an important part of the FDA’s review.
Regarding the review process, Tablets & Capsules stated that the FDA agreed to a rolling review in April of this year and included COMP360 in the Commissioner’s National Priority Voucher program. These arrangements are intended to facilitate review and communication, but the company also cautioned in its announcement that they do not guarantee a faster review or eventual approval.
Compass is preparing for a launch in the first half of 2027, contingent on FDA approval. Even if the application passes review, because the formulation contains a substance classified as Schedule I in the United States, relevant rescheduling by the U.S. Drug Enforcement Administration (DEA) and individual states must also be completed before commercial supply can begin. Regulatory and healthcare delivery hurdles remain between completion of the submission and patients being able to receive treatment.